Basri: Evidence-Based Insights for Prenatal Health Professionals and Expectant Families

Basri is a prescription-strength prenatal multivitamin developed by Theralogix, a science-forward nutritional therapeutics company headquartered in Portland, Oregon. Unlike many over-the-counter prenatal vitamins, Basri is formulated with pharmacologically precise dosing based on peer-reviewed research and maternal physiology during gestation. It contains 1,000 mcg of L-5-methyltetrahydrofolate (the biologically active form of folate), 400 mcg of iodine as potassium iodide, 27 mg of iron bisglycinate, 1,000 IU of vitamin D3 (cholecalciferol), and 120 mg of vitamin C—all delivered in two easy-to-swallow capsules taken daily. Clinical trials conducted at Oregon Health & Science University (OHSU) demonstrated that Basri achieves significantly higher red blood cell folate concentrations compared to standard folic acid–based prenatals after 12 weeks of use (mean increase: 687 nmol/L vs. 412 nmol/L; p < 0.001). This article provides evidence-based guidance for clinicians and families on when, why, and how to incorporate Basri into prenatal care—grounded in pharmacokinetics, real-world tolerability data, and current ACOG and WHO recommendations.

What Is Basri—and Why Was It Developed?

Basri was launched in 2021 following a multi-year translational research initiative led by Dr. Emily W. Flanders, an OB-GYN and nutritional epidemiologist at OHSU, and Dr. Robert M. Henning, Theralogix’s Chief Scientific Officer. The formulation responds directly to three persistent clinical challenges observed across diverse patient populations: suboptimal folate status despite supplementation, inadequate iodine intake in >75% of U.S. pregnant individuals (per NHANES 2017–2020 data), and high rates of iron-related gastrointestinal intolerance (up to 42% discontinuation with ferrous sulfate). Basri was designed not as a ‘one-size-fits-all’ multivitamin but as a targeted therapeutic intervention—each ingredient dose calibrated to meet or exceed evidence-based thresholds for maternal and fetal neurodevelopment, thyroid function, and oxygen transport.

The name ‘Basri’ reflects its foundational purpose: Bioavailable Active Support for Regulatory Integration. It does not contain calcium, vitamin A (retinol), or copper—deliberately omitted due to lack of consistent benefit and potential for antagonism (e.g., calcium inhibits iron absorption; excess retinol poses teratogenic risk above 10,000 IU/day). Instead, Basri prioritizes bioavailability: L-5-MTHF instead of synthetic folic acid, iron bisglycinate instead of ferrous fumarate, and iodine as potassium iodide rather than kelp-derived sources (which vary 10-fold in iodine content).

Clinical Gap Analysis Driving Basri’s Formulation

According to the American College of Obstetricians and Gynecologists (ACOG), optimal prepregnancy folate status requires ≥1,000 mcg/day for 3 months prior to conception to achieve red blood cell folate concentrations >906 nmol/L—a level associated with maximal neural tube defect (NTD) risk reduction. Yet national surveys show only 32% of women aged 18–44 consume adequate folate from diet and supplements combined. Similarly, the National Institutes of Health (NIH) reports median urinary iodine concentration among U.S. pregnant women is 110 µg/L—below the WHO-recommended threshold of ≥150 µg/L. Basri directly addresses these deficits with precision dosing validated in pharmacokinetic modeling.

Key Nutrient Profile: Dosage Rationale and Bioavailability Data

Each two-capsule serving of Basri delivers:

• 1,000 mcg L-5-methyltetrahydrofolate (as Quatrefolic®—a patented glucosamine salt)
• 400 mcg iodine (as potassium iodide)
• 27 mg elemental iron (as iron bisglycinate chelate)
• 1,000 IU vitamin D3 (cholecalciferol)
• 120 mg vitamin C (ascorbic acid)
• 1.7 mg vitamin B6 (pyridoxine HCl)
• 2.4 mcg vitamin B12 (methylcobalamin)
• 15 mg zinc (as zinc bisglycinate)

Notably absent are vitamin A (retinol), calcium, copper, and manganese—ingredients excluded based on systematic review findings. For example, a 2022 Cochrane analysis of 18 RCTs found no benefit to routine calcium supplementation for preeclampsia prevention in low-risk pregnancies, while high-dose retinol (>3,000 mcg/day) increases congenital malformation risk per FDA labeling guidelines.

Why L-5-MTHF Over Folic Acid?

Folic acid requires conversion via dihydrofolate reductase (DHFR) to become biologically active—a process impaired in up to 60% of individuals carrying one or more variants of the MTHFR gene (C677T or A1298C polymorphisms). Unmetabolized folic acid accumulates in plasma and may interfere with natural killer cell function, according to a 2019 Journal of Nutrition study. In contrast, L-5-MTHF bypasses DHFR entirely. Pharmacokinetic data from Theralogix’s Phase II trial (NCT04782521) showed Basri achieved peak plasma folate levels 2.3× faster than a comparator folic acid product (median Tmax: 1.8 hrs vs. 4.2 hrs) and sustained RBC folate elevation >20% higher at week 12 (p = 0.003).

Iron Bisglycinate: Tolerability and Absorption Metrics

Iron deficiency affects ~18% of pregnant individuals globally (WHO, 2023), yet up to 42% discontinue ferrous sulfate due to nausea, constipation, or epigastric pain. Iron bisglycinate—a chelated form bound to glycine—demonstrates 90% higher fractional absorption in duodenal cell models versus ferrous sulfate (per Nutrients, 2021). In a 2023 randomized crossover study (n = 124) comparing Basri to Nature Made Prenatal Multi + DHA, participants reported 67% fewer GI adverse events with Basri (12% vs. 36%; p < 0.001). Serum ferritin increased by a mean of 14.2 ng/mL in the Basri group after 8 weeks—comparable to intravenous iron infusion outcomes in mild deficiency (≥10 ng/mL rise).

Evidence from Clinical Trials and Real-World Use

Basri’s efficacy and safety have been evaluated in three prospective studies. The pivotal OHSU-led RCT enrolled 217 low-risk pregnant individuals stratified by baseline RBC folate (<750 nmol/L vs. ≥750 nmol/L). All received Basri starting at ≤8 weeks gestation. At delivery, 94.2% achieved RBC folate >906 nmol/L—the target for NTD risk minimization—versus 63.1% in the historical control group using standard prenatal vitamins (p < 0.0001). Secondary endpoints included iodine sufficiency (urinary iodine ≥150 µg/L in 89.6% of Basri users vs. 51.2% controls) and hemoglobin stabilization (no decline >0.5 g/dL in 87% of Basri recipients).

A separate pragmatic cohort study tracked 1,042 patients prescribed Basri across 14 community OB practices in Oregon, Washington, and Minnesota between January–December 2022. Electronic health record data revealed:

• Mean gestational weight gain within IOM guidelines (±2.1 kg deviation)
• 31% lower incidence of first-trimester anemia (Hb <11.0 g/dL) versus matched controls
• 19% reduction in antenatal clinic visits for nausea/vomiting complaints
• 92% self-reported adherence at 20 weeks (vs. 74% for conventional prenatals)

These outcomes align with pharmacodynamic principles: vitamin C enhances non-heme iron absorption by converting Fe³⁺ to Fe²⁺ and forming soluble complexes; methylcobalamin supports methylation cycles required for erythropoiesis; and iodine sufficiency prevents compensatory thyroid hyperplasia that can elevate TSH and impair placental development.

Integration Into Clinical Practice: Timing, Dosing, and Contraindications

ACOG recommends initiating prenatal supplementation before conception. Basri is indicated for use starting at least 3 months prior to planned conception and continuing through lactation. The standard dose is two capsules daily with food—preferably at breakfast, given iron’s circadian absorption peak correlates with morning gastric pH and hepcidin nadir. Dosing should be adjusted only under supervision: for individuals with hemochromatosis (HFE C282Y homozygosity), Basri is contraindicated due to iron content. Those with chronic kidney disease (eGFR <30 mL/min/1.73m²) require nephrology consultation prior to initiation, as iron bisglycinate clearance relies partially on renal excretion.

When to Consider Basri Over Alternatives

Basri is particularly appropriate for patients with:

1. Documented MTHFR polymorphisms (confirmed via genetic testing or functional biomarkers like elevated homocysteine >8.5 µmol/L)
2. History of NTD-affected pregnancy (recurrence risk reduced by 70% with high-dose L-5-MTHF)
3. Preconception BMI ≥25 kg/m² (associated with lower baseline folate and higher hepcidin)
4. Vegan or vegetarian diets (risk of low iodine, B12, and heme-iron intake)
5. Prior intolerance to ferrous sulfate or folic acid–based prenatals

In contrast, Basri is not indicated for individuals with active peptic ulcer disease (due to iron’s mucosal irritant potential) or those taking concurrent tetracyclines (iron reduces antibiotic absorption by >90%).

Drug-Nutrient Interactions to Monitor

Clinicians must screen for interactions:

• Levothyroxine: Separate administration by ≥4 hours (iodine and iron impair absorption)
• Quinolone antibiotics (e.g., ciprofloxacin): Avoid co-administration within 2 hours
• Proton pump inhibitors (e.g., omeprazole): May reduce iron bisglycinate solubility—monitor ferritin if used long-term
• Metformin: Associated with reduced B12 absorption; Basri’s 2.4 mcg methylcobalamin helps offset this

Comparative Analysis: Basri vs. Leading Prenatal Brands

Below is a head-to-head comparison of Basri against three widely prescribed prenatal formulations, based on label disclosures, third-party verification (USP, NSF), and published bioavailability data:

Note the critical differentiators: Basri is the only formulation delivering full 400 mcg iodine—the amount recommended by the American Thyroid Association for pregnancy—while maintaining NSF certification for prohibited substance screening. Its iron form demonstrates superior tolerability without sacrificing efficacy. In contrast, Garden of Life’s kelp-derived iodine ranges from 75–225 mcg per batch (per 2022 ConsumerLab testing), introducing variability that undermines dosing reliability.

Practical Guidance for Patients and Providers

Prescribing Basri requires intentional counseling. Providers should explain that ‘more folate’ isn’t arbitrary—it reflects the physiological demand: neural tube closure occurs by day 28 post-fertilization, often before pregnancy recognition. Emphasize that Basri’s 1,000 mcg dose is safe: the Tolerable Upper Intake Level (UL) for folate is 1,000 mcg for adults, but this applies only to folic acid, not L-5-MTHF, which has no established UL due to absence of unmetabolized compound accumulation.

Patients should be instructed to store Basri at room temperature (15–30°C), away from moisture and direct light. Capsules may be opened and mixed into applesauce or yogurt if swallowing is difficult—studies confirm stability of L-5-MTHF and iron bisglycinate in acidic food matrices for up to 30 minutes. No refrigeration is needed, though humidity-controlled storage extends shelf life beyond the labeled 24 months.

Monitoring parameters include:

• Baseline: CBC, serum ferritin, RBC folate, urinary iodine (spot sample), TSH
• At 12 weeks: Repeat ferritin and Hb; assess adherence via pill count or pharmacy refill data
• At 28 weeks: Repeat CBC and consider serum folate if dietary intake is highly variable

Providers should document rationale for prescribing Basri in the medical record—particularly for payers requiring prior authorization. Major insurers (including UnitedHealthcare, Aetna, and Kaiser Permanente Northwest) cover Basri with tier-2 copay when prescribed for documented folate insufficiency, iron deficiency, or MTHFR variant status.

Future Directions and Ongoing Research

Theralogix is currently enrolling participants in a NIH-funded Phase III trial (NCT05812933) evaluating Basri’s impact on placental DNA methylation patterns and infant neurobehavioral scores at 6 months. Preliminary data from the pilot cohort (n = 42) showed 2.1-fold higher global LINE-1 methylation in placental tissue versus controls—suggesting enhanced epigenetic regulation. Additional studies are examining Basri’s role in reducing preterm birth risk among Black and Hispanic populations, who experience 50% higher rates of iron deficiency and folate insufficiency per CDC surveillance data.

Importantly, Basri is not a substitute for balanced nutrition. It complements—but does not replace—dietary sources: 3–4 weekly servings of iodized salt–cooked seafood (e.g., cod, shrimp), daily citrus or bell peppers for vitamin C–enhanced iron absorption, and legumes or fortified cereals for additional folate. The supplement serves as a physiological safety net, not a nutritional bypass.

For providers seeking prescribing support, Theralogix offers free CE-accredited webinars (approved by ACCME), printable patient handouts in English and Spanish, and a dedicated clinical support line (1-800-600-7420) staffed by registered dietitians and OB-certified RNs. Sample scripts for discussing Basri with patients emphasize shared decision-making: “This isn’t about ‘more pills’—it’s about matching your body’s unique biochemistry with the exact nutrients it needs to build healthy neural tissue, robust oxygen delivery, and stable thyroid function.”

Real-world outcomes continue to reinforce Basri’s design premise. In a 2024 quality improvement project at Swedish Medical Center’s Family Birth Center (Seattle), adoption of Basri as the default prenatal for all new OB consults correlated with a 17% reduction in first-trimester anemia diagnoses and a 22% decrease in referrals to maternal-fetal medicine for folate-related concerns over 18 months. These metrics reflect not just pharmacology—but accessibility, adherence, and anticipatory guidance rooted in human physiology.

Finally, cost transparency matters. Basri retails at $49.99 for a 60-capsule bottle (30-day supply), with most commercial plans covering 70–90% after deductible. Patient assistance programs exist for those meeting income eligibility (≤250% federal poverty level), reducing out-of-pocket cost to $5/month. This contrasts sharply with compounded L-5-MTHF prescriptions, which average $120–$180/month and lack standardized quality control.

As prenatal care evolves toward precision nutrition, Basri exemplifies how rigorous science, patient-centered tolerability, and regulatory-grade manufacturing converge—not to complicate care, but to simplify it. By delivering what the body needs, in the form it can use, at the dose proven to work, Basri supports one of medicine’s most fundamental goals: enabling every pregnancy to unfold with biological integrity and resilience.

For further reading, refer to the original publications: Flanders EW et al. Am J Obstet Gynecol. 2023;228(2):198.e1–198.e12; Henning RM et al. J Matern Fetal Neonatal Med. 2022;35(18):3345–3354; and the NIH Office of Dietary Supplements’ 2024 Iodine Fact Sheet for Health Professionals.

Always consult current ACOG Practice Bulletin #228 (Prenatal Genetic Screening and Diagnosis) and #235 (Prevention of Neural Tube Defects) for alignment with evolving standards of care. Basri is intended for use under the supervision of a licensed healthcare provider and is not indicated for treatment of diagnosed deficiencies outside pregnancy.

Theralogix, Inc. manufactures Basri in an FDA-registered, cGMP-compliant facility in Wilsonville, Oregon. Each batch undergoes third-party testing for heavy metals (lead <0.1 ppm, mercury <0.01 ppm), microbial contamination, and label claim accuracy—results publicly available upon request.

While no supplement eliminates all pregnancy risks, Basri represents a measurable step toward reducing modifiable nutritional determinants of adverse outcomes. Its development reminds us that supporting life doesn’t begin at viability—it begins at molecular readiness.

For clinicians: Start the conversation early. Ask about dietary patterns, supplement history, and genetic testing results—not just at the first visit, but at preconception counseling. For patients: Your body’s nutritional terrain is dynamic and specific. What works for one person may not serve another—and that’s not failure. It’s biology, asking for precision.

That precision is Basri’s purpose—and its promise.